Search
for
Sort by
Research 481–510 of 1000+
- Insights from real-world data: clinical features and treatment patterns of Compound Jinqiancao Granules in patients with prostatitis
- P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study
- Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- EPH225 Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity Among Adults in Taiwan
- Post‐finasteride syndrome: real or myth?
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- Comment on 'A prospective real world study evaluating serum levels of arginine and cysteine in females with chronic telogen effluvium: do we really need blanket prescription with amino acid supplementation?'
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Minoxidil in severe hypertension with renal failure
- Severe Hypertension in Children With Renal Disease: Treatment With Minoxidil
- Emerging roles of Sox6 in the renal and cardiovascular system
- Use of Single‐Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma
- Regenerative Versus Nonregenerative Repair of the Renal Medulla After Reversal of Ureteral Obstruction
- Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
- Effect of high-fructose diet on the renal cortex of adult male albino rats
- Early Clinical Expressions of Insulin Resistance: The Real Enemy to Look For
- The coudability sign of alopecia areata: the real story
- Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States